(Q38380461)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

review article

1 reference

title

Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Jessica L Mega

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

14 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

386

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

9990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

281-291

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777662%20AND%20SRC:MED&resulttype=core&format=json

Mechanisms of thrombus formation

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Novel antiplatelet agents in acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Low-dose aspirin for the prevention of atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

1 reference

7 January 2021

Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Drug insight: aspirin resistance--fact or fashion?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

The story of clopidogrel and its predecessor, ticlopidine: Could these major antiplatelet and antithrombotic drugs be discovered and developed today?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Prehospital ticagrelor in ST-segment elevation myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Ef

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

1 reference

7 January 2021

High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Antiplatelet therapy and proton pump inhibition: clinician update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Clopidogrel with or without omeprazole in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Cigarette smoking and clopidogrel interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Grapefruit juice inhibits the metabolic activation of clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Bedside monitoring to adjust antiplatelet therapy for coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reac

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Normalization of platelet reactivity in clopidogrel-treated subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Inefficacy of platelet transfusion to reverse ticagrelor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Platelet thrombin receptor antagonism and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Vorapaxar in the secondary prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

The discovery of dicumarol and its sequels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

National surveillance of emergency department visits for outpatient adverse drug events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

The mechanism of the interaction between amiodarone and warfarin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

A randomized trial of genotype-guided dosing of warfarin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

A pharmacogenetic versus a clinical algorithm for warfarin dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Pharmacogenetics and coumarin dosing--recalibrating expectations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Dabigatran versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Apixaban versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Edoxaban versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Apixaban with antiplatelet therapy after acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

Aspirin selectively inhibits prostaglandin production in human platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960243-4

7 January 2021

10.1016/S0140-6736(15)60243-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference